Portfolio Lab

Qiagen N.v.

  • Stock
  • Ticker QGEN
  • ISIN NL0015002SN0
  • NYSE
  • US listing in dollars

Health care · Biotechnology · Netherlands

$49.30 −0.66%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Qiagen N.v. since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

QGENGlobal equities (VT)

$10,000 grew to $17,789. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −42.7% in 05/2026, measured from the peak in 09/2021. The old peak has not been reached again yet.

1-year return
+8.4%
5-year return p.a.
−2.2%
10-year return p.a.
+5.9%
Volatility p.a.
27.1%
Largest decline
−42.7%

Financial statements

Amounts in $ millions from the company's annual financial reports, earnings per share in $ per ordinary share

Fiscal year202020212022202320242025
Income statement
Revenue1,8702,2522,1431,9651,9782,090
Gross profit1,2281,4461,3761,2289621,293
Operating income384636533413117468
EBITDA594855745624327670
Net income7453757648560437
Earnings per share0.312.312.502.100.272.00
Balance sheet
Total assets5,9716,2096,3526,1745,7566,348
Liabilities3,4883,3502,9622,3072,1562,426
Equity2,4832,8593,3893,8673,6013,922
Cash597880730667663839
Long-term debt1,8751,0401,4188681,2841,444
Cash flow
Operating cash flow492676751493708692
Capital expenditure-80-139-56-41-68-77
Free cash flow412537695451640615

Annual returns

Best year 2020 at +56.4%, weakest 2023 at −12.9%. 6 of 9 full years were positive. * partial year.

Key metrics

Key figures as of 21 Nov 2026 from the company's latest annual financial report, amounts converted to US dollars at the ECB reference rate. Valuation and market cap appear only where price and earnings per share reliably refer to the same share.

Valuation

Market cap
€9.7bn
Market cap in trading currency
$10.7bn
Enterprise value
$11.3bn
P/E
24.7
P/S
5.13
P/B
2.73
EV/Sales
5.42
EV/EBITDA
16.9
Earnings yield
4.1%
FCF yield
5.7%

Results (latest fiscal year)

Revenue
$2.09bn
Gross profit
$1.29bn
EBITDA
$670m
Net income
$437m
Earnings per share
$2.00
Revenue growth
+5.7%
Earnings growth
+630.6%

Profitability

Gross margin
61.9%
Operating margin
22.4%
Net margin
20.9%
Return on equity
11.6%
Return on assets
6.9%

Balance sheet and cash flow

Cash
$839m
Financial debt
$1.44bn
Debt/equity %
37
Current ratio
3.91
Book value per share
$18.04
Operating cash flow
$692m
Free cash flow
$615m

Dividend

Dividend yield
5.35%
Dividend (12 months)
$2.64
Yield (12 months)
5.35%
Payout ratio
12%
Ex-dividend date
7 Jul 2026

Shares and trading

Shares outstanding
217m
Volume
2.63m
Avg. volume 3 months
3.57m
Relative volume
0.7

Price and technicals

Price
$49.30
1 day
−0.7%
52-week high
$55.66
52-week low
$32.63
Distance to 52-week high
−11.4%
Distance to 52-week low
+51.1%
Distance to 50-day line
+4.4%
Distance to 200-day line
+16.3%
RSI (14)
52
Volatility 1M
6.7%

Performance

1 week
−1.2%
1 month
−1.8%
3 months
+18.0%
6 months
+40.2%
YTD
+4.1%
1 year
+5.4%

Dates

Fiscal year end
31 Dec 2025

Frequently asked questions

How has QGEN performed since 11/2016?

$10,000 grew to $17,789 by 20 Nov 2026, which is +5.9% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is QGEN?

Volatility was 27.1% per year, measured on monthly returns. The largest decline from a peak was −42.7%, with the low in 05/2026.

How does QGEN compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, QGEN returned +5.9% at 27.1%. The correlation of monthly returns was 0.22; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Why does this page show a US listing?

The figures use the stock's listing traded in the US. On individual days its path differs slightly from the price on the home exchange.

Not investment advice. Key figures and financial statements calculated from the company's annual financial reports, without guarantee; key figures converted to US dollars at the ECB reference rate, statements in the currency of the report.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Qiagen N.v. (QGEN): Return and risk | Portfolio Lab